Company intelligence / Profile preview

Corcept Therapeutics

Menlo Park, California, United Statesorpha.net ↗

Ownership: Public · CORT
Employees: ~400
Development stage: Commercial

Overview

Corcept has a marketed product Korlym (mifepristone) for Cushing's syndrome and multiple clinical programs in development. Q2 2024 showed strong financial results with revenue of $163.8 million, a 39% increase year-over-year. The company has several late-stage clinical trials with results expected by year-end 2024.

Therapeutic areas: OncologyEndocrinologyNeurologyMetabolic Disorders
Modalities: Small moleculesCortisol modulators
Industry: Biotech

Drug pipeline

12 assets

relacorilant

Approved

11 more assets in the full pipeline.

Request access →

Partnerships

Academic collaborations with universities worldwide

Financials

Market cap: $12.3B
Total revenue: $256.1M
Enterprise value: $12B

Beyond the preview

Go deeper on Corcept Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Corcept Therapeutics.

Explore the full profile